Korean J Endocr Surg.
2014 Sep;14(3):131-137. 10.0000/kjes.2014.14.3.131.
Clinical Implication of BRAF Mutation in Thyroid Cancer
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. yjparkmd@snu.ac.kr
- KMID: 2144011
- DOI: http://doi.org/10.0000/kjes.2014.14.3.131
Abstract
- The BRAF(V600E) mutation is the most common genetic alteration and presents in 40~80% of all papillary thyroid cancer (PTC), showing the highest prevalence in the Korean population, close to 80%. Previous studies published in the past 10 years showed a significant correlation between BRAF(V600E) mutation and poor prognostic outcomes of PTC, including recurrence and mortality. Therefore, its clinical application for the diagnosis of thyroid nodule or for decisions regarding the management policy by prediction of the prognosis of thyroid cancer has been proposed. However, some recent studies have reported conflict results, and there appear to be growing concerns regard to the cost-benefit of tests for detection of the BRAF(V600E) mutation. In this paper, we reviewed previous studies regarding the BRAF(V600E) mutation and attempted to evaluate the clinical implication of the BRAF(V600E) mutation in clinical practice.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Different Expression of BRAF(V600E) Mutation in Patients with Papillary Thyroid Carcinomas Coexisting with or without Benign Thyroid Nodules
- Association of BRAF(V600E) Mutation with Poor Clinical Prognostic Factors and Ultrasonographic Findings in Cases of Papillary Thyroid Carcinoma
- Thyroid Cancer, Iodine, and Gene Mutation
- Expressions of miRNAs in Papillary Thyroid Carcinoma and Their Associations with the BRAFV600EMutation and Clinicopathological Features.
- The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma
